Latest News and Press Releases

Route 92 Medical announced results from an independent real-world study of its HiPoint Reperfusion System and plans for a 500-patient SUMMIT RISE study.

Route 92 Medical names med tech industry veterans Mitch Hill and Lucas Buchanan to its board of directors.

Route 92 Medical announces results of the SUMMIT MAX randomized clinical trial and receipt of a 510(k) clearance for the HiPoint 88 Reperfusion System.

Route 92 Medical and Q'Apel Medical have settled their patent litigation.

Route 92 Medical receives Australian Therapeutic Goods Administration approval for its portfolio of neurovascular interventional products.

First-of-its-kind multicenter study demonstrates the utility of the Monopoint system in procedures to treat idiopathic intracranial hypertension.

Route 92 Medical announces $50 million series F extension equity financing to support its commercial expansion.

Route 92 Medical announces the commercial launch of its FreeClimb 88 catheter system.

Route 92 Medical announces FDA 510(k) clearance for its FreeClimb 54 reperfusion system, part of its growing portfolio of neurovascular devices.

Route 92 Medical announces completion of enrollment in the SUMMIT MAX clinical trial studying their .088" HiPoint Reperfusion Catheter.